PMID:
Curr Pharm Des. 2020 May 23. Epub 2020 May 23. PMID: 32445451
Abstract Title:
AMPK and its activator Berberine in the Treatment of Neurodegenerative Diseases.
Abstract:
Neurodegenerative disorders are heterogeneous diseases associated with either acute or progressive neurodegeneration, causing the loss of neurons and axons in the central nervous system (CNS), showing high morbidity and mortality, and there are few effective therapies. Here we summarized the energy sensor adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) and its agonist berberine can combat the common underlying pathological events of neurodegeneration including oxidative stress, neuroinflammation, mitochondrial disorder, glutamate excitotoxicity, apoptosis, autophagy disorder and neurovascular units disruption. The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-κB (NF-κB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK). It is hoped that this review will provide a powerful basis for further scientific exploration and development of berberine's therapeutic potential against neurodegeneration.
Health Time 